|1.||Meschler, J P: 2 articles (06/2001 - 11/2000)|
|2.||Howlett, A C: 2 articles (06/2001 - 11/2000)|
|3.||Madras, B K: 1 article (06/2001)|
|4.||Darmani, N A: 1 article (02/2001)|
|5.||Conley, T J: 1 article (11/2000)|
04/01/1982 - "[Treatment of refractory cytostatic agent-induced vomiting with the synthetic cannabinoid levonantradol]."
12/01/1985 - "The current phase I trial was undertaken to determine: 1) the maximally tolerated dose; 2) the side effects at the different dosage levels; and 3) to evaluate the antiemetic efficacy of levonantradol in patients receiving emesis-producing chemotherapy. "
12/01/1985 - "Phase 1 trial of levonantradol in chemotherapy-induced emesis."
08/01/1981 - "Levonantradol, a new synthetic cannabinoid, was examined for antiemetic effectiveness in 27 patients with refractory chemotherapy-induced emesis. "
08/01/1981 - "Oral levonantradol in the treatment of chemotherapy-induced emesis: preliminary observations."
06/01/1983 - "Twenty-three patients with severe nausea and vomiting refractory to conventional anti-emetic therapy were entered into an open phase II study of levonantradol. "
08/01/1981 - "It is suggested that a combination of oral and parenteral levonantradol may prove to be a very effective program to relieve the otherwise disabling problems of persistent nausea and vomiting."
01/01/1985 - "Antiemetic efficacy of levonantradol compared to delta-9-tetrahydrocannabinol for chemotherapy-induced nausea and vomiting."
07/15/1983 - "Levonantradol for the treatment of chemotherapy-induced nausea and vomiting."
06/01/1983 - "Levonantradol: a synthetic cannabinoid in the treatment of severe chemotherapy-induced nausea and vomiting resistant to conventional anti-emetic therapy."
01/01/1983 - "A dose-ranging study with oral levonantradol was performed in 20 cancer patients. "
08/01/1981 - "The effects of levonantradol hydrochloride on tumor growth and therapy."
11/30/1984 - "[Levonantradol as an antiemetic in cancer chemotherapy]."
08/01/1981 - "We report here our initial observations with the antiemetic levonantradol in 12 patients with advanced solid tumors receiving cytotoxic polychemotherapy. "
08/01/1981 - "These data support the use of levonantradol in conjunction with chemotherapy in cancer patients."
08/01/1981 - "However, levonantradol did increase the latency of appearance of fully kindled seizures at the 400 micrograms/kg dose. "
08/01/1981 - "Levonantradol administered in doses of 100 to 400 micrograms/kg did not block any components of the motor seizure. "
08/01/1981 - "Levonantradol, at doses of 0.32 and 3.2 mg/kg subcutaneously, which did not block the convulsant effect of pentylenetetrazol, enhanced both the potency and efficacy of diazepam in elevating the absolute threshold of pentylenetetrazol for eliciting clonic seizures. "
08/01/1981 - "Although the mechanism underlying this potentiation of the antiepileptic effects of valproic acid and diazepam remains unknown, levonantradol may have potential as adjunctive therapy in the treatment of complex partial seizures."
08/01/1981 - "The anticonvulsant effects of the cannabinoid derivative levonantradol and its ability to potentiate the anticonvulsant effects of diazepam and valproic acid were studied in rats with previously established amygdala-kindled seizures. "
01/01/1985 - "These results extend observations for the acute effects of l-nantradol and clonidine to operant responding under a schedule of continuous shock avoidance. "
07/01/1985 - "Marked tolerance developed for the shock-increasing effects of morphine (3.0 mg/kg) and l-nantradol (0.3 mg/kg) within 10 to 15 sessions, but only partial tolerance developed for shock-increasing effects of clonidine (0.3 mg/kg) after up to 35 sessions. "
07/01/1985 - "Morphine and l-nantradol resulted in markedly higher shock intensities only at doses that severely disrupted responding, whereas clonidine resulted in higher shock intensities over a broader dose range without disrupting responding. "
07/01/1985 - "The opioid morphine, the antihypertensive clonidine and the cannabinoid l-nantradol each resulted in a dose-related increase in shock intensity, although l-nantradol and clonidine were 10 to 30 times more potent than morphine. "
01/01/1983 - "Nantradol (0.1-0.3 mg/kg), levonantradol (0.03-0.1 mg/kg), or N-methyl levonantradol (0.01-0.03 mg/kg) increased the level at which shock was maintained, but did not change rates of responding. "
|9.||Morphine (MS Contin)
|1.||Drug Therapy (Chemotherapy)
|5.||Combination Drug Therapy (Combination Chemotherapy)